DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.
Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules. The disease is caused 30% by HCV infection, resulting in a risk of severe complications and death. Since the use of direc...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2023-02-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/41811 |
| _version_ | 1811171887524347904 |
|---|---|
| author | Kamila Abram Patryk Banaś Justyna Adamus Jakub Rafał Pierzchała Katarzyna Bednarz Natalia Sobańska Aleksandra Paulina Banasiak Rafał Teichman Jakub Kasprowicz Michał Hyjek |
| author_facet | Kamila Abram Patryk Banaś Justyna Adamus Jakub Rafał Pierzchała Katarzyna Bednarz Natalia Sobańska Aleksandra Paulina Banasiak Rafał Teichman Jakub Kasprowicz Michał Hyjek |
| author_sort | Kamila Abram |
| collection | DOAJ |
| description |
Introduction
Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules. The disease is caused 30% by HCV infection, resulting in a risk of severe complications and death. Since the use of direct-acting antivirals ( DAAs) for the treatment of chronic HCV, sustained virological response (SVR) rates have begun to increase, even in treatment-resistant cases. Studies have also shown that DAAs may have applications in other viral diseases and even In the treatment of breast cancer.
Aim of the study
The purpouse of our study was to review scientific articles to show the efficiency and potential use of DAAs in the treatment of chronic HCV, and to identify possible directions for further research.
Methods and materials
We reviewed the English literature in the PubMed, using the key words: "simeprevir" ; "sofosbuvir" ; "velpatasvir" ; "telaprevir" ; "chronic hepatitis C".
Results
Studies have shown that the therapeutic regimens currently being designed with (DAAs) offer the possibility of treating almost the entire population with hepatitis C, while reducing side effects of interferon therapy such as increased AST, ALT activities, diarrhoea, vomiting, nausea and depression. They remain effective and tolerable, regardless of the stage of cirrhosis and associated serious co-morbidities. Analysis of studiem shows, that DAAs also show efficacy against other disease such as breast cancer, MRSA infections, SARS-CoV-2 or flavivirus infection.
Conclusion
All (DAAs) are effective in the treatment of patients with HCV, including cirrhosis. They result in significant improvements in prognosis and clinical outcomes. Promising results have been obtained in published data on the effect of DAAs against disease entities other than HCV, suggesting the rationale for future clinical trials to further the hypothesis of the increased potential of these drugs.
|
| first_indexed | 2024-04-10T17:21:40Z |
| format | Article |
| id | doaj.art-79d969a0fd414b9188e61612d6eb13d1 |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-04-10T17:21:40Z |
| publishDate | 2023-02-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-79d969a0fd414b9188e61612d6eb13d12023-02-05T11:43:10ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062023-02-0113310.12775/JEHS.2023.13.03.029DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.Kamila Abram0Patryk Banaś1Justyna Adamus2Jakub Rafał Pierzchała3Katarzyna Bednarz4Natalia Sobańska5Aleksandra Paulina Banasiak6Rafał Teichman7Jakub Kasprowicz8Michał Hyjek9SP ZOZ MSWiA w Katowicach im. Sierżanta Grzegorza Załogi w KatowicachSzpital Zakonu Bonifratrów pw. Aniołów Stróżów w KatowicachZespół Szpitali Miejskich w ChorzowieSamodzielny Publiczny Szpital Kliniczny Nr 4 w LublinieWojewódzki Szpital Specjalistyczny Nr 1 imienia Fryderyka Chopina w RzeszowieWojewódzki Szpital Specjalistyczny Nr 1 imienia Fryderyka Chopina w Rzeszowie1 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ w LublinieWojewódzki Szpital Specjalistyczny Nr 1 imienia Fryderyka Chopina w RzeszowieSamodzielny Publiczny Szpital Kliniczny Nr 4 w LublinieIndependent Public Clinical Hospital No.1 in Lublin Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules. The disease is caused 30% by HCV infection, resulting in a risk of severe complications and death. Since the use of direct-acting antivirals ( DAAs) for the treatment of chronic HCV, sustained virological response (SVR) rates have begun to increase, even in treatment-resistant cases. Studies have also shown that DAAs may have applications in other viral diseases and even In the treatment of breast cancer. Aim of the study The purpouse of our study was to review scientific articles to show the efficiency and potential use of DAAs in the treatment of chronic HCV, and to identify possible directions for further research. Methods and materials We reviewed the English literature in the PubMed, using the key words: "simeprevir" ; "sofosbuvir" ; "velpatasvir" ; "telaprevir" ; "chronic hepatitis C". Results Studies have shown that the therapeutic regimens currently being designed with (DAAs) offer the possibility of treating almost the entire population with hepatitis C, while reducing side effects of interferon therapy such as increased AST, ALT activities, diarrhoea, vomiting, nausea and depression. They remain effective and tolerable, regardless of the stage of cirrhosis and associated serious co-morbidities. Analysis of studiem shows, that DAAs also show efficacy against other disease such as breast cancer, MRSA infections, SARS-CoV-2 or flavivirus infection. Conclusion All (DAAs) are effective in the treatment of patients with HCV, including cirrhosis. They result in significant improvements in prognosis and clinical outcomes. Promising results have been obtained in published data on the effect of DAAs against disease entities other than HCV, suggesting the rationale for future clinical trials to further the hypothesis of the increased potential of these drugs. https://apcz.umk.pl/JEHS/article/view/41811simeprevirsofosbuvirvelpatasvirtelaprevirchronic hepatitis C |
| spellingShingle | Kamila Abram Patryk Banaś Justyna Adamus Jakub Rafał Pierzchała Katarzyna Bednarz Natalia Sobańska Aleksandra Paulina Banasiak Rafał Teichman Jakub Kasprowicz Michał Hyjek DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application. Journal of Education, Health and Sport simeprevir sofosbuvir velpatasvir telaprevir chronic hepatitis C |
| title | DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application. |
| title_full | DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application. |
| title_fullStr | DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application. |
| title_full_unstemmed | DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application. |
| title_short | DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application. |
| title_sort | daa directly acting antivirals as a new more efficient solution of the chronic hepatitis c treatment and theirs various application |
| topic | simeprevir sofosbuvir velpatasvir telaprevir chronic hepatitis C |
| url | https://apcz.umk.pl/JEHS/article/view/41811 |
| work_keys_str_mv | AT kamilaabram daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication AT patrykbanas daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication AT justynaadamus daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication AT jakubrafałpierzchała daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication AT katarzynabednarz daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication AT nataliasobanska daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication AT aleksandrapaulinabanasiak daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication AT rafałteichman daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication AT jakubkasprowicz daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication AT michałhyjek daadirectlyactingantiviralsasanewmoreefficientsolutionofthechronichepatitisctreatmentandtheirsvariousapplication |